Crewe Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
Other funds holding LGND
JT
CAM
Crewe Advisors's LGND Position: Q2 2026 in Review
Crewe Advisors reduced its Ligand Pharmaceuticals (LGND) stake by 48% in Q2 2026, selling an estimated $20.5K and leaving 94 shares worth $29.7K. The position accounts for ﹤0.01% of the portfolio, ranked #530.
Crewe Advisors first reported a position in LGND in Q2 2024 and has held it in 5 quarters since. The position peaked at $36.1K in Q1 2026. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Crewe Advisors held 94 shares of Ligand Pharmaceuticals worth $29.7K as of Q2 2026.
- Crewe Advisors sold 87 Ligand Pharmaceuticals shares in Q2 2026, an estimated $20.5K.
- Ligand Pharmaceuticals made up ﹤0.01% of Crewe Advisors's portfolio in Q2 2026, its #530 holding.
- Crewe Advisors first reported a position in Ligand Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
- Crewe Advisors's Ligand Pharmaceuticals position peaked at $36.1K in Q1 2026.
- 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.